16 Prostate Cancer Clinical Trials in Omaha, NE (2026)

Q: How do I join a clinical trial in Omaha?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Omaha research site will contact you.

Recruiting Prostate Cancer Studies in Omaha

NCT06520345Recruiting

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen ...

Omaha, NEPHASE3520 participantsTelix Pharmaceuticals (Innovations) Pty Limited

View Study Details

NCT06014255Recruiting

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12...

Omaha, NEPHASE2219 participantsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

View Study Details

NCT06217822Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below...

Omaha, NEPHASE1198 participantsBayer

View Study Details

NCT04729114Recruiting

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an ...

Omaha, NEPHASE1174 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07590934Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prost...

Omaha, NEPHASE1152 participantsAstraZeneca

View Study Details

NCT04363164Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to dete...

Omaha, NEPHASE2150 participantsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

View Study Details

NCT07237269Recruiting

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patie...

Omaha, NEPHASE2140 participantsUniversity of Nebraska

View Study Details

NCT07581184Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the prelimi...

Omaha, NEPHASE1138 participantsAktis Oncology, Inc.

View Study Details

NCT06879041Recruiting

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275....

Omaha, NEPHASE1136 participantsAstraZeneca

View Study Details

NCT06531499Recruiting

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSM...

Omaha, NEPHASE1106 participantsNovartis Pharmaceuticals

View Study Details

NCT05413850Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer....

Omaha, NEPHASE182 participantsBlue Earth Therapeutics Ltd

View Study Details

NCT06801236Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC)....

Omaha, NEPHASE167 participantsAcerand Therapeutics (Hong Kong) Limited

View Study Details

NCT07189871Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relap...

Omaha, NEPHASE161 participantsRadiopharm Theranostics, Ltd

View Study Details

NCT06549465Recruiting

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administratio...

Omaha, NEPHASE260 participantsConvergent Therapeutics

View Study Details

NCT07234981Recruiting

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

Purpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining can...

Omaha, NEPHASE254 participantsUniversity of Nebraska

View Study Details

NCT04868604Recruiting

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer....

Omaha, NEPHASE154 participantsClarity Pharmaceuticals Ltd

View Study Details

About Prostate Cancer Clinical Trials in Omaha

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 16 prostate cancer clinical trials recruiting participants in Omaha, NE. These studies are seeking a combined 2,311 participants. Research is being sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bayer and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Omaha — FAQ

Are there prostate cancer clinical trials in Omaha?

Yes, there are 16 prostate cancer clinical trials currently recruiting in Omaha, NE. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Omaha?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Omaha research site will contact you about next steps.

Are clinical trials in Omaha free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Omaha studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 16 active trials in Omaha are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 18, 2026 from ClinicalTrials.gov